The global liquid biopsy market was valued at USD 9.63 billion in 2024 and is expected to grow from USD 11.66 billion in 2025 to USD 58.64 billion by 2032, registering a CAGR of 25.9% during the forecast period. In 2024, North America led the global liquid biopsy market, accounting for a 54.43% share.
The liquid biopsy market is emerging as a transformative tool in cancer diagnostics and monitoring. It enables the detection of tumor-derived materials such as circulating tumor DNA (ctDNA), exosomes, and circulating tumor cells (CTCs) through a non-invasive blood draw. This technology offers significant advantages over traditional tissue biopsies, including real-time disease tracking, early detection, and treatment response assessment. Growing demand for personalized medicine, increasing cancer prevalence, and advancements in next-generation sequencing technologies are key factors driving the expansion of the global liquid biopsy market.
Continue reading for more details:
https://www.fortunebusinessinsights.com/liquid-biopsy-market-102506
Market Segmentation:
The liquid biopsy market can be segmented based on biomarker type, application, cancer type, and end-user:
By Biomarker Type: The market includes circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), RNA, and exosomes.
By Application: Key applications include early cancer detection, treatment monitoring, recurrence detection, and companion diagnostics.
By Cancer Type: The market addresses various cancers such as breast cancer, lung cancer, colorectal cancer, prostate cancer, and others.
By End-User: Major end-users include hospitals, diagnostic laboratories, academic research centers, and biotechnology companies.
Key Companies Featured in the Liquid Biopsy Market Report:
Guardant Health (U.S.)
PERSONALIS, INC. (U.S.)
FOUNDATION MEDICINE, INC. (U.S.)
Natera, Inc. (U.S.)
Illumina, Inc. (U.S.)
Hoffmann-La Roche Ltd (Switzerland)
Menarini Silicon Biosystems, Inc. (Italy)
Thermo Fisher Scientific Inc. (U.S.)
QIAGEN (Germany)
Bio-Rad Laboratories, Inc. (U.S.)
Market Growth:
The liquid biopsy market is experiencing rapid growth due to its potential to transform oncology care. It offers a less invasive, quicker, and repeatable alternative for tumor profiling, treatment selection, and disease monitoring. The integration of liquid biopsy into clinical workflows is expanding as oncologists seek to enhance patient outcomes with more precise and timely diagnostics. Continued advancements in genomic technologies, next-generation sequencing (NGS), and biomarker discovery are further fueling the market’s expansion.
Restraining Factors:
Despite its promising potential, the liquid biopsy market faces several challenges. These include the high cost of tests, limited standardization across diagnostic platforms, and concerns about test sensitivity and specificity. Regulatory hurdles and the need for robust clinical validation also hinder market penetration. Moreover, limited awareness among healthcare professionals and patients in certain regions may slow adoption rates.
Regional Insights:
The liquid biopsy market exhibits diverse growth trends across different regions, shaped by varying levels of technological advancement, healthcare infrastructure, and cancer prevalence. North America holds the leading position in the market, driven by robust research and development activities, a high adoption rate of advanced diagnostic tools, and strong support from regulatory and reimbursement frameworks. Europe follows closely, with countries investing heavily in oncology research and personalized medicine initiatives, promoting the integration of liquid biopsy into clinical practice. The Asia-Pacific region is emerging as a high-growth area due to its rapidly expanding healthcare sector, increasing awareness of early cancer detection, and rising investments in biotechnology and genomics. In Latin America and the Middle East & Africa, the liquid biopsy market is gradually gaining traction, supported by efforts to modernize healthcare systems, improve cancer screening programs, and increase access to innovative diagnostics. As each region advances at its own pace, global adoption of liquid biopsy is expected to rise significantly in the coming years.
Key Industry Developments:
February 2024: Twist Bioscience Corporation launched a cfDNA library preparation kit to advance liquid biopsy research.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower,
Baner - Mahalunge Road,
Baner, Pune-411045,
Maharashtra, India.
Phone:
U.S.: +1 424 253 0390
U.K.: +44 2071 939123
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com